

# SAFETY DATA SHEET

### 1. Identification

Product identifier	Quinapril Hydrochloride
Other means of identification	
Catalog number	1593401
Chemical name	3-Isoquinolinecarboxylic acid, 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]- 1,2,3,4-tetrahydro-, monohydrochloride, [3S-[2[R*(R*)],3R*]]
Recommended use	Specified quality tests and assay use only.
Recommended restrictions	Not for use as a drug. Not for administration to humans or animals.
Manufacturer/Importer/Supplier	r/Distributor information

Company name Address	U. S. Pharmacopeia 12601 Twinbrook Parkway Rockville MD 20852-1790 US	
Telephone	RS Technical Services	301-816-8129
Website	www.usp.org	
E-mail	RSTECH@usp.org	
Emergency phone number	CHEMTREC within US & Canada	1-800-424-9300
	CHEMTREC outside US & Canada	+1 703-527-3887

### 2. Hazard(s) identification

Physical hazards	Not classified.	
Health hazards	Reproductive toxicity	Category 1
	Specific target organ toxicity, repeated exposure	Category 2 (cardiovascular system)
OSHA hazard(s)	Not classified.	

Label elements



Signal word	Danger
Hazard statement	May damage fertility or the unborn child. May cause damage to organs (cardiovascular system) through prolonged or repeated exposure.
Precautionary statement	t de la constant de l
Prevention	Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Wear protective gloves/protective clothing/eye protection/face protection.
Response	If exposed or concerned: Get medical advice/attention.
Storage	Store locked up.
Disposal	Dispose of contents/container to an approved disposal site.
Hazard(s) not otherwise classified (HNOC)	Not classified.

# 3. Composition/information on ingredients

Substance			
Hazardous components Chemical name	Common name and synonyms	CAS number	%
Quinapril Hydrochloride		82586-55-8	100

### 4 First-aid measures

Inhalation	If breathing is difficult, remove to fresh air and keep at rest in a position comfortable for breathing. Call a physician if symptoms develop or persist.
Skin contact	Rinse skin with water/shower. Get medical attention if irritation develops and persists.
Eye contact	Rinse with water. Get medical attention if irritation develops and persists.
Ingestion	Rinse mouth. If ingestion of a large amount does occur, call a poison control center immediately.
Most important symptoms/effects, acute and delayed	Not available.
Indication of immediate medical attention and special treatment needed	Provide general supportive measures and treat symptomatically. Treatment of ACE inhibitor overdose should include the following: Administer activated charcoal as a slurry. For hypotension, infuse isotonic fluid. If hypotension persists, administer dopamine or norepinephrine. To reverse hypotension in patients not responding to volume or pressor infusions, treat with angiotensin infusion. Naloxone has also been successful in reversing hypotension. For angioedema, administer antihistamines and corticosteroids. Monitor airway carefully and administer oxygen. May be removable by hemodialysis. [Meditext 2011 and USP DI 2011]
General information	Remove from exposure. Remove contaminated clothing. For treatment advice, seek guidance from an occupational health physician or other licensed health-care provider familiar with workplace chemical exposures. In the United States, the national poison control center phone number is 1-800-222-1222. If person is not breathing, give artificial respiration. If breathing is difficult, give oxygen if available. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention.
5. Fire-fighting measures	
Suitable extinguishing media	Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials.
Unsuitable extinguishing media	None known.
Specific hazards arising from the chemical	No unusual fire or explosion hazards noted.
Special protective equipment and precautions for firefighters	Wear suitable protective equipment.
Fire-fighting equipment/instructions	As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.
Specific methods	Cool containers exposed to flames with water until well after the fire is out.
6. Accidental release meas	ures
Personal precautions, protective equipment and emergency procedures	Keep unnecessary personnel away. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Avoid inhalation of dust from the spilled material. Wear appropriate personal protective equipment.
Methods and materials for containment and cleaning up	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid the generation of dusts during clean-up. For waste disposal, see section 13 of the SDS. Wash spill site.
7. Handling and storage	

Precautions for safe handling As a general rule, when handling USP Reference Standards, avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Clean equipment and work surfaces with suitable detergent or solvent after use. After removing gloves, wash hands and other exposed skin thoroughly.

Conditions for safe storage, Store in tight container as defined in the USP-NF. This material should be handled and stored per including any incompatibilities label instructions to ensure product integrity.

### 8. Exposure controls/personal protection

#### **Exposure limit values**

#### Industrial Use

Material	Туре	Value	
Quinapril Hydrochloride (CAS 82586-55-8)	TWA	0.1 mg/m3	
Biological limit values	No biological exposure limits noted	for the ingredient(s).	

No biological exposure limits noted for the ingredient(s).

Appropriate engineering controls	<ul> <li>Airborne exposure should be controlled primarily by engineering controls such as general dilution ventilation, local exhaust ventilation, or process enclosure. Local exhaust ventilation is generally preferred to general exhaust because it can control the contaminant at its source, preventing dispersion into the work area. An industrial hygiene survey involving air monitoring may be used to determine the effectiveness of engineering controls. Effectiveness of engineering controls intended for use with highly potent materials should be assessed by use of nontoxic surrogate materials.</li> <li>Local exhaust ventilation such as a laboratory fume hood or other vented enclosure is recommended, particularly for grinding, crushing, weighing, or other dust-generating procedures.</li> </ul>
Individual protection measure	s, such as personal protective equipment
Eye/face protection	Safety glasses with sideshields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI Z87 or CSA stamp) is preferred. Maintain eyewash facilities in the work area.
Skin protection	
Hand protection	Chemically compatible gloves. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic nonlatex gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy.
Other	For handling of laboratory scale quantities, a cloth lab coat is recommended. Where significant quantities are handled, work clothing may be necessary to prevent take-home contamination.
Respiratory protection	Where respirators are deemed necessary to reduce or control occupational exposures, use NIOSH-approved respiratory protection and have an effective respirator program in place (applicable U.S. regulation OSHA 29 CFR 1910.134).
Thermal hazards	Not available.
General hygiene considerations	Handle in accordance with good industrial hygiene and safety practice.

# 9. Physical and chemical properties

Appearance	White to off-white powder.
Physical state	Solid.
Form	Powder.
Odor	Not available.
Odor threshold	Not available.
рН	Not available.
Melting point/freezing point	246.2 - 266 °F (119 - 130 °C)
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not applicable.
Upper/lower flammability or expl	osive limits
Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Explosive limit - lower (%)	Not available.
Explosive limit - upper (%)	Not available.
Vapor pressure	< 0.0000001 kPa at 25 °C
Vapor density	Not available.
Relative density	Not available.
Solubility in water	Soluble.
Partition coefficient (n-octanol/water)	0.33
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Other information	
Molecular formula	C25H30N2O5 . HCI
Molecular weight	474.98
Percent volatile	0.5 %

Freely soluble in aqueous solvents and soluble in methanol and in acetonitrile.

# 10. Stability and reactivity

Solubility (other)

Reactivity	No reactivity hazards known.
Chemical stability	Stable at normal conditions.
Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
Conditions to avoid	None known.
Incompatible materials	Strong oxidizing agents.
Hazardous decomposition products	NOx. Cl Irritating and/or toxic fumes or gases. Emits toxic fumes under fire conditions.

# 11. Toxicological information

### Information on likely routes of exposure

Ingestion	Based on available data, the classification criteria are not met.	
Inhalation	Due to lack of data the classification is not possible.	
Skin contact	Due to lack of data the classification is not possible.	
Eye contact	Due to lack of data the classification is not possible.	
Symptoms related to the physical, chemical, and toxicological characteristics	ACE inhibitors: Dizziness. Skin rash. Itching. Fever. Joint pain. Cough. Chest pain. Slow heart rate. Alteration in or loss of taste. Swelling. Bleeding. Bruising. Blood in urine or stools. Pinpoint red spots on skin. Confusion. Irregular heartbeat. Difficulty breathing. Numbness or tingling in hands, feet, or lips. Tiredness. Weakness. Heaviness of legs. Irritability. Dry mouth. Muscle cramps.	
Delayed and immediate effects of exposure	ACE inhibitors: Gout. Thrombocytopenia. Hyperkalemia. Electrolyte imbalance. Pancreatitis. Liver toxicity. Kidney failure. Zinc loss.	
Cross sensitivity	Persons sensitive to one ACE inhibitor may be sensiti	ve to this material also.
Medical conditions aggravated by exposure	ACE inhibitors: Angioedema. Active alcoholism. Severe auto-immune disease. Cerebrovascular or coronary insufficiency. Diabetes mellitus. Kidney transplant. Impaired liver or kidney function. Hyperkalemia. Bone marrow depression. Volume depletion caused by severe dietary sodium restriction or dialysis.	
Acute toxicity	Based on available data, the classification criteria are	not met.
Product	Species	Test Results
Quinapril Hydrochloride (CAS 8258	6-55-8)	
Acute		
Oral		
LD50	Mouse	14/8 mg/kg
	Rat	3541 mg/kg
Skin corrosion/irritation	Due to lack of data the classification is not possible.	
Serious eye damage/eye irritation	Due to lack of data the classification is not possible.	
Respiratory sensitization	Due to lack of data the classification is not possible.	
Skin sensitization	Based on available data, the classification criteria are	not met.
Sensitization Guinea Pig Maximization T Result: Non-sensitizing. Species: Guinea pig Organ: Skin.	Fest	
Germ cell mutagenicity	Based on available data, the classification criteria are studies were negative in a related material.	not met. In vivo and in vitro mutagenicity
Carcinogenicity	Based on available data, the classification criteria are be a carcinogen by IARC, ACGIH, NTP, or OSHA.	not met. This product is not considered to
100 mg/kg/day Carcinoger Result: Not carcinogenic. I increased incidence of me hemangiomas and skin/su Species: Rat Test Duration: 104 weeks 75 mg/kg/day Carcinogeni Result: Not carcinogenic. Species: Mouse Test Duration: 104 weeks	nicity study n female rats, there was an senteric lymph node bcutaneous lipomas. city study	

May damage fertility or the unborn child. The therapeutic use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with serious fetal and newborn injury, including growth retardation, renal impairment, oligohydramnios, hypocalvaria, fetal pulmonary hypoplasia, reduced fetal blood pressure, newborn anuria, patent ductus steriosus, and death. Prematurity can also occur. ACE inhibitors have demonstrated little or no teratogenicity in animal studies.

Reproductivity 300 mg/kg/day Reproducti Result: No adverse effects Species: Rat	vity study on fertility or reproduction.
Specific target organ toxicity - single exposure	Based on available data, the classification criteria are not met.
Specific target organ toxicity - repeated exposure	May cause damage to organs (cardiovascular system) through prolonged or repeated exposure.
Aspiration hazard	Based on available data, the classification criteria are not met.

#### 12. Ecological information

Ecotoxicity	No ecotoxicity data noted for the ingredient(s).
Persistence and degradability	No data is available on the degradability of this product.
Bioaccumulative potential	Not available.
Mobility in soil	Not available.
Other adverse effects	Not available.

### 13. Disposal considerations

Disposal instructions	This product, in its present state, when discarded or disposed of, is not a hazardous waste according to Federal regulations (40 CFR 261.4 (b)(4)). Under RCRA, it is the responsibility of
	the user of the product to determine, at the time of disposal, whether the product meets RCRA criteria for hazardous waste. Dispose in accordance with all applicable regulations.
Local disposal regulations	Not available.
Hazardous waste code	Not regulated.
Waste from residues / unused products	Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).
Contaminated packaging	Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.

### 14. Transport information

#### DOT

Not regulated as a hazardous material by DOT.

#### ΙΑΤΑ

Not regulated as a dangerous good.

Transport in bulk according to	No information available.
Annex II of MARPOL 73/78 and	
the IBC Code	

#### 15. Regulatory information

US federal regulations	This product is a "Hazardous Chemical" as defined by the OSHA Hazard Communication Standard, 29 CFR 1910.1200. CERCLA/SARA Hazardous Substances - Not applicable.
	One or more components are not listed on TSCA.
Superfund Amendments and Rea	authorization Act of 1986 (SARA)
Hazard categories	Immediate Hazard - No Delayed Hazard - No Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No
SARA 302 Extremely hazardous substance	No
SARA 311/312 Hazardous chemical	No

Other federal regulations		
Safe Drinking Water Act (SDWA)	Not regulated.	
Food and Drug Administration (FDA)	Not regulated.	
US state regulations	This product does not contain a chemical known to the State of defects or other reproductive harm.	California to cause cancer, birth
International Inventories		
Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No

Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

\*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

### 16. Other information, including date of preparation or last revision

Issue date Revision date Version # Further information	01-24-2007 04-11-2013 03 Not available.
Disclaimer	USP Reference Standards are sold for chemical test and assay purposes only, and NOT for human consumption. The information contained herein is applicable solely to the chemical substance when used as a USP Reference Standard and does not necessarily relate to any other use of the substance described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP Reference Standards are intended for use by persons having technical skill and at their own discretion and risk. This information has been developed by USP staff from sources considered reliable but has not been independently verified by the USP. Therefore, the USP Convention cannot guarantee the accuracy of the information in these sources nor should the statements contained herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE is made with respect to the information contained herein.
Revision Information	This document has undergone significant changes and should be reviewed in its entirety.